Impax Asset Management Group plc boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 85,000 shares of the company's stock after purchasing an additional 35,000 shares during the quarter. Impax Asset Management Group plc owned approximately 0.08% of Neurocrine Biosciences worth $9,794,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of NBIX. Vanguard Group Inc. increased its position in Neurocrine Biosciences by 2.3% during the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company's stock worth $1,369,673,000 after buying an additional 220,598 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Neurocrine Biosciences by 9.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company's stock valued at $339,790,000 after buying an additional 216,500 shares during the period. AQR Capital Management LLC increased its holdings in shares of Neurocrine Biosciences by 23.0% during the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company's stock worth $166,959,000 after buying an additional 228,444 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Neurocrine Biosciences by 1.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company's stock worth $128,639,000 after buying an additional 13,069 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in Neurocrine Biosciences by 40.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company's stock valued at $97,828,000 after acquiring an additional 203,934 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.
Analyst Ratings Changes
Several research firms have recently weighed in on NBIX. Royal Bank of Canada reduced their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research note on Friday, October 4th. HC Wainwright reissued a "buy" rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Piper Sandler upgraded shares of Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Robert W. Baird increased their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an "outperform" rating in a report on Friday, August 2nd. Finally, Oppenheimer boosted their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an "outperform" rating in a research note on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $163.91.
Read Our Latest Stock Report on Neurocrine Biosciences
Neurocrine Biosciences Stock Down 4.4 %
NBIX stock traded down $5.44 during trading on Friday, hitting $117.44. 1,255,345 shares of the company's stock traded hands, compared to its average volume of 867,191. The stock has a market capitalization of $11.89 billion, a price-to-earnings ratio of 31.49 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 52 week low of $107.84 and a 52 week high of $157.98. The stock has a fifty day moving average price of $118.50 and a two-hundred day moving average price of $132.66.
Neurocrine Biosciences Profile
(
Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See Also
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
